Twice monthly (aspirational) recap of the NephJC journal club. NephJC reviews the most important manuscripts which are driving nephrology forward and improving... more
Listen now on
Episodes
FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for... more
Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something. No. The answer is no. But... more
NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one... more
So this one has been on the hard drive gathering dust for quite awhile. There were significant technical problems (in... more
The fluids wars have been going back and forth and now have another big win. This time in transplant.
On Friday of #KidneyWk, at the City Winery in Philadelphia, The Filtrate collaborated with The Curbsiders to do a live... more
We love Kidney Week and the quintessential event at Kidney Week is the Late Break and High Impact Clinical Trial... more
Inaxaplin is a small molecule that is in trials for APOL1 associated kidney disease. Genome guided medicine comes to nephrology.
Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients.The Filtrate:Joel TopfNayan... more
Another dogma shredding trial about diuretics, this time torsemide goes up against king furosemide and its ability to prevent rehospitalization... more